CommentaryPredictive cancer genomics—what do we need?
References (10)
- et al.
Primary medical (neo-adjuvant) chemotherapy for operable breast cancer
Eur J Cancer
(1993) - et al.
Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma
Eur J Surg Oncol
(2003) - et al.
A guide to microarray experiments—an open letter to the scientific journals
Lancet
(2002) - et al.
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
J Natl Cancer Inst
(1990) - et al.
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
J Clin Oncol
(1999)
There are more references available in the full text version of this article.
Cited by (19)
Emerging issues of the expression profiling technologies for the study of gynecologic cancer
2005, American Journal of Obstetrics and GynecologyCitation Excerpt :This finding provides the impetus for further studies to delineate the mechanisms of drug resistance. However, there are several considerations regarding the expectations and the conclusions that can be drawn from such approaches.77 The clinical parameters in these studies need to be concrete with well-described criteria, avoiding any arbitrary classification.
Exceptional matters
2004, LancetDose and schedule as determinants of outcomes in chemotherapy for breast cancer
2004, Seminars in OncologyGenes causing inherited cancer as beacons to identify the mechanisms of chemoresistance
2004, Trends in Molecular MedicinePrognostic relevance of acquired uniparental disomy in serous ovarian cancer
2015, Molecular CancerMolecular profiling currently offers no more than tumour morphology and basic immunohistochemistry
2010, Breast Cancer Research
Copyright © 2003 Elsevier Ltd. All rights reserved.